Lexeo Therapeutics, Inc. (LXEO)

In October 2025, Lexeo announced progress in FDA discussions and positive interim clinical data for LX2006, closing an oversubscribed $154 million equity financing. In November 2025, the FDA approved the analytical comparability report for LX2006 manufacturing processes. In January 2026, Lexeo reported positive interim clinical data from the HEROIC PKP2 Phase I/II clinical trial evaluating LX2020, but its stock dropped 23% due to investor skepticism. In February 2026, Lexeo submitted the final registrational trial design for the SUNRISE-FA 2 pivotal study to the FDA. In March 2026, clinical data from the LX2020 program were presented at the ACC Annual Meeting, and Lexeo announced a research collaboration with Johnson & Johnson. As of March 27, 2026, Lexeo Therapeutics' stock price was $5.460, down 23.96% in March, with a one-year high of $10.990 and a low of $1.450.

As a clinical-stage genetic medicine company, Lexeo Therapeutics, Inc. does not currently have commercialized products on the market, and therefore, there is no direct demand seasonality for its products or services.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing therapies for hereditary and acquired diseases, particularly genetically defined cardiovascular conditions and APOE4-associated Alzheimer's disease. Its pipeline includes LX2006 for Friedreich ataxia cardiomyopathy, LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, LX2021 for inherited cardiac muscle disorders, LX2022 for hypertrophic cardiomyopathy, and LX1001 for APOE4 homozygous Alzheimer's disease.

Lexeo Therapeutics, Inc. is headquartered in New York City and collaborates with academic institutions and contract research organizations across North America and Europe to support its clinical development efforts.

Lexeo Therapeutics has generally maintained a positive brand reputation due to advancements in its clinical pipeline and positive regulatory interactions. Positive clinical data, regulatory designations, and strategic partnerships have contributed to this. However, a stock drop in January 2026, despite positive analyst ratings, may have temporarily impacted investor perception.

Lexeo Therapeutics, Inc. is primarily owned by institutional shareholders, who hold approximately 56% to 76.79% of the company's stock. Insiders own around 1.24% to 10.29%, while retail investors hold approximately 10% to 21.98%. Major institutional owners include Janus Henderson Group Plc, Ra Capital Management, L.p., and BlackRock, Inc.